tiprankstipranks
Abbott Laboratories (CH:ABT)
NYSE:ABT
Switzerland Market
ABT
Abbott Laboratories
RESEARCH TOOLSreports

Abbott Laboratories (ABT) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

ABT Analyst Ratings

Strong Buy
20Ratings
Strong Buy
16 Buy
4 Hold
0 Sell
Based on 20 analysts giving stock ratings to
Abbott
Laboratories
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ABT Stock 12 Month Forecast

Average Price Target

CHF95.37
▲(25.48% Upside)
Based on 20 Wall Street analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is CHF95.37 with a high forecast of CHF115.82 and a low forecast of CHF72.08. The average price target represents a 25.48% change from the last price of CHF76.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"66":"CHF66","91":"CHF91","116":"CHF116","78.5":"CHF78.5","103.5":"CHF103.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":115.81601316999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF115.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95.3659828725,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF95.37</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72.08129491,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF72.08</span>\n  </div></div>","useHTML":true}}],"tickPositions":[66,78.5,91,103.5,116],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.5,71.2166163976923,74.93323279538461,78.64984919307692,82.36646559076922,86.08308198846153,89.79969838615384,93.51631478384616,97.23293118153845,100.94954757923077,104.66616397692306,108.38278037461538,112.09939677230768,{"y":115.81601316999999,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.5,69.64353714403846,71.78707428807692,73.93061143211538,76.07414857615385,78.2176857201923,80.36122286423077,82.50476000826923,84.64829715230769,86.79183429634615,88.93537144038461,91.07890858442308,93.22244572846154,{"y":95.3659828725,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.5,67.85240730076923,68.20481460153846,68.55722190230769,68.90962920307692,69.26203650384615,69.61444380461538,69.96685110538462,70.31925840615385,70.67166570692308,71.02407300769231,71.37648030846154,71.72888760923077,{"y":72.08129491,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":103.884,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.884,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.411,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.411,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.411,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.888,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.91,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.91,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.48,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.468,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.007,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.5,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF115.82Average Price TargetCHF95.37Lowest Price TargetCHF72.08
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on CH:ABT
Larry Biegelsen
Wells Fargo
Wells Fargo
CHF88.28
Buy
16.16%
Upside
Reiterated
06/26/26
Wells Fargo Remains a Buy on Abbott Laboratories (ABT)
Piper Sandler Analyst forecast on CH:ABT
Adam Maeder
Piper Sandler
Piper Sandler
CHF93.14
Buy
22.55%
Upside
Reiterated
06/22/26
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (NASDAQ: TENX), Abbott Laboratories (NYSE: ABT) and AbbVie (NYSE: ABBV)
Citi Analyst forecast on CH:ABT
Joanne Wuensch
Citi
Citi
CHF87.47→CHF72.08
Buy
-5.16%
Downside
Reiterated
06/17/26
Citi sum-of-the-parts analysis shows Abbott share upsideCiti sum-of-the-parts analysis shows Abbott share upside
Bank of America Securities Analyst forecast on CH:ABT
Travis Steed
Bank of America Securities
Bank of America Securities
CHF97.19→CHF82.61
Buy
8.70%
Upside
Reiterated
06/12/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), HeartFlow, Inc. (NASDAQ: HTFL) and Neurogene (NASDAQ: NGNE)
TD Cowen Analyst forecast on CH:ABT
Josh Jennings
TD Cowen
TD Cowen
―
Buy
―
Reiterated
06/09/26
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (NASDAQ: TNGX), Cartesian Therapeutics (NASDAQ: RNAC) and Abbott Laboratories (NYSE: ABT)
Goldman Sachs Analyst forecast on CH:ABT
David Roman
Goldman Sachs
Goldman Sachs
CHF98→CHF91.52
Buy
20.42%
Upside
Reiterated
05/31/26
Abbott Laboratories: Buy Rating Reaffirmed on Improving 2026 Growth Outlook and Margin Expansion Potential, with Price Target Trimmed to $113
Daiwa Analyst forecast on CH:ABT
Narumi Nakagiri
Daiwa
Daiwa
CHF91.52→CHF74.51
Hold
-1.96%
Downside
Downgraded
04/21/26
Abbott downgraded to Neutral from Outperform at DaiwaAbbott downgraded to Neutral from Outperform at Daiwa
Mizuho Securities Analyst forecast on CH:ABT
Anthony Petrone
Mizuho Securities
Mizuho Securities
CHF101.24→CHF93.14
Hold
22.55%
Upside
Reiterated
04/20/26
Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (NYSE MKT: PTHS), Abbott Laboratories (NYSE: ABT) and Pfizer (NYSE: PFE)
Barclays Analyst forecast on CH:ABT
Matt Miksic
Barclays
Barclays
CHF116.63→CHF115.82
Buy
52.39%
Upside
Assigned
04/20/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Eli Lilly & Co (NYSE: LLY) and Ionis Pharmaceuticals (NASDAQ: IONS)
UBS Analyst forecast on CH:ABT
Danielle Antalffy
UBS
UBS
CHF127.96→CHF109.34
Buy
43.86%
Upside
Reiterated
04/20/26
UBS Sticks to Their Buy Rating for Abbott Laboratories (ABT)
Jefferies Analyst forecast on CH:ABT
Matthew Taylor
Jefferies
Jefferies
CHF117.44→CHF109.34
Buy
43.86%
Upside
Reiterated
04/17/26
Analysts' Top Healthcare Picks: Rapport Therapeutics, Inc. (RAPP), Abbott Laboratories (ABT)
Oppenheimer Analyst forecast on CH:ABT
Suraj Kalia
Oppenheimer
Oppenheimer
CHF106.91→CHF93.14
Buy
22.55%
Upside
Reiterated
04/17/26
Abbott price target lowered to $115 from $132 at OppenheimerAbbott price target lowered to $115 from $132 at Oppenheimer
Stifel Nicolaus Analyst forecast on CH:ABT
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
CHF117.44→CHF97.19
Buy
27.88%
Upside
Assigned
04/17/26
Abbott price target lowered to $120 from $145 at StifelAbbott price target lowered to $120 from $145 at Stifel
William Blair Analyst forecast on CH:ABT
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
04/17/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and BioAge Labs, Inc. (NASDAQ: BIOA)
Benchmark Co. Analyst forecast on CH:ABT
Bruce Jackson
Benchmark Co.
Benchmark Co.
CHF117.44→CHF97.19
Buy
27.88%
Upside
Reiterated
04/17/26
Abbott price target lowered to $120 from $145 at BenchmarkAbbott price target lowered to $120 from $145 at Benchmark
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on CH:ABT
Larry Biegelsen
Wells Fargo
Wells Fargo
CHF88.28
Buy
16.16%
Upside
Reiterated
06/26/26
Wells Fargo Remains a Buy on Abbott Laboratories (ABT)
Piper Sandler Analyst forecast on CH:ABT
Adam Maeder
Piper Sandler
Piper Sandler
CHF93.14
Buy
22.55%
Upside
Reiterated
06/22/26
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (NASDAQ: TENX), Abbott Laboratories (NYSE: ABT) and AbbVie (NYSE: ABBV)
Citi Analyst forecast on CH:ABT
Joanne Wuensch
Citi
Citi
CHF87.47→CHF72.08
Buy
-5.16%
Downside
Reiterated
06/17/26
Citi sum-of-the-parts analysis shows Abbott share upsideCiti sum-of-the-parts analysis shows Abbott share upside
Bank of America Securities Analyst forecast on CH:ABT
Travis Steed
Bank of America Securities
Bank of America Securities
CHF97.19→CHF82.61
Buy
8.70%
Upside
Reiterated
06/12/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), HeartFlow, Inc. (NASDAQ: HTFL) and Neurogene (NASDAQ: NGNE)
TD Cowen Analyst forecast on CH:ABT
Josh Jennings
TD Cowen
TD Cowen
―
Buy
―
Reiterated
06/09/26
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (NASDAQ: TNGX), Cartesian Therapeutics (NASDAQ: RNAC) and Abbott Laboratories (NYSE: ABT)
Goldman Sachs Analyst forecast on CH:ABT
David Roman
Goldman Sachs
Goldman Sachs
CHF98→CHF91.52
Buy
20.42%
Upside
Reiterated
05/31/26
Abbott Laboratories: Buy Rating Reaffirmed on Improving 2026 Growth Outlook and Margin Expansion Potential, with Price Target Trimmed to $113
Daiwa Analyst forecast on CH:ABT
Narumi Nakagiri
Daiwa
Daiwa
CHF91.52→CHF74.51
Hold
-1.96%
Downside
Downgraded
04/21/26
Abbott downgraded to Neutral from Outperform at DaiwaAbbott downgraded to Neutral from Outperform at Daiwa
Mizuho Securities Analyst forecast on CH:ABT
Anthony Petrone
Mizuho Securities
Mizuho Securities
CHF101.24→CHF93.14
Hold
22.55%
Upside
Reiterated
04/20/26
Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (NYSE MKT: PTHS), Abbott Laboratories (NYSE: ABT) and Pfizer (NYSE: PFE)
Barclays Analyst forecast on CH:ABT
Matt Miksic
Barclays
Barclays
CHF116.63→CHF115.82
Buy
52.39%
Upside
Assigned
04/20/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Eli Lilly & Co (NYSE: LLY) and Ionis Pharmaceuticals (NASDAQ: IONS)
UBS Analyst forecast on CH:ABT
Danielle Antalffy
UBS
UBS
CHF127.96→CHF109.34
Buy
43.86%
Upside
Reiterated
04/20/26
UBS Sticks to Their Buy Rating for Abbott Laboratories (ABT)
Jefferies Analyst forecast on CH:ABT
Matthew Taylor
Jefferies
Jefferies
CHF117.44→CHF109.34
Buy
43.86%
Upside
Reiterated
04/17/26
Analysts' Top Healthcare Picks: Rapport Therapeutics, Inc. (RAPP), Abbott Laboratories (ABT)
Oppenheimer Analyst forecast on CH:ABT
Suraj Kalia
Oppenheimer
Oppenheimer
CHF106.91→CHF93.14
Buy
22.55%
Upside
Reiterated
04/17/26
Abbott price target lowered to $115 from $132 at OppenheimerAbbott price target lowered to $115 from $132 at Oppenheimer
Stifel Nicolaus Analyst forecast on CH:ABT
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
CHF117.44→CHF97.19
Buy
27.88%
Upside
Assigned
04/17/26
Abbott price target lowered to $120 from $145 at StifelAbbott price target lowered to $120 from $145 at Stifel
William Blair Analyst forecast on CH:ABT
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
04/17/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and BioAge Labs, Inc. (NASDAQ: BIOA)
Benchmark Co. Analyst forecast on CH:ABT
Bruce Jackson
Benchmark Co.
Benchmark Co.
CHF117.44→CHF97.19
Buy
27.88%
Upside
Reiterated
04/17/26
Abbott price target lowered to $120 from $145 at BenchmarkAbbott price target lowered to $120 from $145 at Benchmark
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abbott Laboratories

3 Months
Jayson BedfordRaymond James
Success Rate
32/44 ratings generated profit
73%
Average Return
+4.72%
Copying Jayson Bedford's trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +4.72% per trade.
1 Year
Jayson BedfordRaymond James
Success Rate
35/44 ratings generated profit
80%
Average Return
+16.57%
Copying Jayson Bedford's trades and holding each position for 1 Year would result in 79.55% of your transactions generating a profit, with an average return of +16.57% per trade.
2 Years
Matthew TaylorJefferies
Success Rate
14/21 ratings generated profit
67%
Average Return
+27.53%
Copying Matthew Taylor's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +27.53% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABT Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
1
1
0
0
0
Buy
31
32
38
35
40
Hold
1
2
6
6
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
33
35
44
41
45
In the current month, ABT has received 40 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. ABT average Analyst price target in the past 3 months is 95.37.
Each month's total comprises the sum of three months' worth of ratings.

ABT Financial Forecast

ABT Earnings Forecast

Next quarter’s earnings estimate for ABT is CHF1.04 with a range of CHF1.02 to CHF1.07. The previous quarter’s EPS was CHF0.93. ABT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.
Next quarter’s earnings estimate for ABT is CHF1.04 with a range of CHF1.02 to CHF1.07. The previous quarter’s EPS was CHF0.93. ABT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.

ABT Sales Forecast

Next quarter’s sales forecast for ABT is CHF10.15B with a range of CHF9.87B to CHF10.29B. The previous quarter’s sales results were CHF9.04B. ABT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.
Next quarter’s sales forecast for ABT is CHF10.15B with a range of CHF9.87B to CHF10.29B. The previous quarter’s sales results were CHF9.04B. ABT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.

ABT Stock Forecast FAQ

What is CH:ABT’s average 12-month price target, according to analysts?
Based on analyst ratings, Abbott Laboratories’s 12-month average price target is 95.37.
    What is CH:ABT’s upside potential, based on the analysts’ average price target?
    Abbott Laboratories has 25.48% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Abbott Laboratories a Buy, Sell or Hold?
          Abbott Laboratories has a consensus rating of Strong Buy, which is based on 16 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Abbott Laboratories’s share price target?
            The average share price target for Abbott Laboratories is 95.37. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is CHF115.82 ,and the lowest forecast is CHF72.08. The average share price target represents 25.48% Increase from the current price of CHF76.
              What do analysts say about Abbott Laboratories?
              Abbott Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
                How can I buy shares of Abbott Laboratories?
                To buy shares of CH:ABT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.